Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 106069

Result Summary for 106069

Result Summary

Protocol ID:	106069
Clinical Study ID:	106069
Official Title:	Study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV vaccine GSK580299 in healthy female subjects aged 10-25 years
Phase:	phase 3
Study Indications or Diseases:	Infections, Papillomavirus
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Watson-Jones D et al. (2013) High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. Sex Transm Infect. doi:10.1136/sextrans-2012-050685. [Epub ahead of print]. Sow PS et al. (2012) Safety and immunogenicity of Human Papillomavirus-16/18 AS04-adjuvanted vaccine: A randomized trial in 10-25-year-old HIV-seronegative African girls and young women. J Infect Dis. doi: 10.1093/infdis/jis619. [Epub ahead of print]. Sow PS. et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in African preteen/adolescent girls and young women. Abstract presented at the African Organisation for Research and Training in Cancer (AORTIC). Cairo, Egypt, November 30 – December 3, 2011. Kiviat N et al. Immunisation of African pre-teen/adolescent girls and young women with the HPV-16/18 AS04-adjuvanted vaccine. Abstract presented at South African Society of Obstetricians and Gynaecologists - O & G Update 2011. Pretoria, South Africa, 5-7 May 2011.